title: Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
abstract: Pseudomonas aeruginosa isolates (n = 3,902) from 75 U.S. medical centers were tested against ceftazidime-avibactam and comparator agents by the reference broth microdilution method. Overall, 96.9% of the strains were susceptible (MIC, ≤8 μg/ml) to ceftazidime-avibactam, while the rates of susceptibility for ceftazidime, meropenem, and piperacillin-tazobactam were 83.8, 81.9, and 78.5%, respectively. Multidrug-resistant and extensively drug-resistant phenotypes were observed in 14.9 and 8.7% of the strains, respectively, and 81.0 and 73.7% of the strains were susceptible to ceftazidime-avibactam, respectively.
authors.affiliation: JMI Laboratories, North Liberty, Iowa, USA helio-sader@jmilabs.com.
authors.forename: Helio S
authors.initials: HS
authors.lastname: Sader
authors.affiliation: JMI Laboratories, North Liberty, Iowa, USA.
authors.forename: Mariana
authors.initials: M
authors.lastname: Castanheira
authors.affiliation: JMI Laboratories, North Liberty, Iowa, USA.
authors.forename: Rodrigo E
authors.initials: RE
authors.lastname: Mendes
authors.affiliation: JMI Laboratories, North Liberty, Iowa, USA.
authors.forename: Robert K
authors.initials: RK
authors.lastname: Flamm
authors.affiliation: JMI Laboratories, North Liberty, Iowa, USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: Farrell
authors.affiliation: JMI Laboratories, North Liberty, Iowa, USA.
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D053961:Azabicyclo Compounds / Q000494:pharmacology*; D002442:Ceftazidime / Q000494:pharmacology*; D004338:Drug Combinations; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010878:Piperacillin / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D000078142:Tazobactam; D013845:Thienamycins / Q000494:pharmacology; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; D004338:Drug Combinations; D013845:Thienamycins; C000595613:avibactam, ceftazidime drug combination; D010397:Penicillanic Acid; D002442:Ceftazidime; D000077731:Meropenem; D000078142:Tazobactam; D010878:Piperacillin
references.citation: Clin Infect Dis. 2002 Mar 1;34(5):634-40
references.pmid: 11823954
references.citation: Drugs. 1985 Feb;29(2):105-61
references.pmid: 3884319
references.citation: Clin Microbiol Rev. 2009 Oct;22(4):582-610
references.pmid: 19822890
references.citation: J Antimicrob Chemother. 2010 Nov;65(11):2376-81
references.pmid: 20801783
references.citation: Antimicrob Agents Chemother. 2011 Jun;55(6):2992-4
references.pmid: 21422208
references.citation: Trends Microbiol. 2011 Aug;19(8):419-26
references.pmid: 21664819
references.citation: Curr Opin Microbiol. 2011 Oct;14(5):550-5
references.pmid: 21840248
references.citation: Clin Microbiol Infect. 2012 Mar;18(3):268-81
references.pmid: 21793988
references.citation: Infect Control Hosp Epidemiol. 2013 Jan;34(1):1-14
references.pmid: 23221186
references.citation: Ann N Y Acad Sci. 2013 Jan;1277:105-14
references.pmid: 23346860
references.citation: Antimicrob Agents Chemother. 2014;58(3):1684-92
references.pmid: 24379201
references.citation: J Antimicrob Chemother. 2014 Jul;69(7):1804-14
references.pmid: 24603963
references.citation: Antimicrob Agents Chemother. 2014 Sep;58(9):5297-305
references.pmid: 24957838
references.citation: Antimicrob Agents Chemother. 2014 Oct;58(10):5704-13
references.pmid: 25022578
references.citation: Antimicrob Agents Chemother. 2014 Nov;58(11):6844-50
references.pmid: 25182652
references.citation: J Chemother. 2014 Dec;26(6):333-8
references.pmid: 24125508